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Glossary of Terms
Definitions from Article 2 of the
Convention on Biological Diversity:

•

•

•

“Biological diversity” means the variability among living organisms from all
sources including, inter alia, terrestrial,
marine and other aquatic ecosystems
and the ecological complexes of which
they are part; this includes diversity
within species, between species and of
ecosystems.
“Biological resources” includes genetic
resources, organisms or parts thereof,
populations, or any other biotic component of ecosystems with actual or
potential use or value for humanity.
“Biotechnology” means any technological application that uses biological
systems, living organisms, or derivatives
thereof, to make or modify products or
processes for specific use.

•

“Country of origin of genetic resources”
means the country which possesses
those genetic resources in in-situ conditions.

•

“Country providing genetic resources”
means the country supplying genetic
resources collected from in-situ sources,
including populations of both wild and
domesticated species, or taken from
ex-situ sources, which may or may not
have originated in that country.

•

“Domesticated or cultivated species”
means species in which the evolutionary

process has been influenced by humans
to meet their needs.

•

“Ecosystem” means a dynamic complex
of plant, animal and micro-organism
communities and their non-living environment interacting as a functional unit.

•

“Ex-situ conservation” means the conservation of components of biological
diversity outside their natural habitats.

•

“Genetic material” means any material
of plant, animal, microbial or other origin
containing functional units of heredity.

•

“Genetic resources” means genetic
material of actual or potential value (tangible and intangible).

•

“Habitat” means the place or type of
site where an organism or population
naturally occurs.

•

“In-situ conditions” means conditions
where genetic resources exist within
ecosystems and natural habitats, and, in
the case of domesticated or cultivated
species, in the surroundings where they
have developed their distinctive properties.

•

“In-situ conservation” means the conservation of ecosystems and natural
habitats and the maintenance and
recovery of viable populations of species in their natural surroundings and, in
the case of domesticated or cultivated
species, in the surroundings where they
have developed their distinctive properties.

Acronyms
•

“Protected area” means a geographically defined area which is designated
or regulated and managed to achieve
specific conservation objectives.

NP

Nagoya Protocol on Access and 		
Benefit Sharing

CBD

Convention on Biological Diversity

“Sustainable use” means the use of
components of biological diversity in
a way and at a rate that does not lead
to the long-term decline of biological
diversity, thereby maintaining its potential to meet the needs and aspirations of
present and future generations.

DNA

Deoxyribonucleic acid

PIC

Prior Informed Consent

ABS

Access and Benefit Sharing

DOO

Disclosure of Origin

COP

Conference of the Parties

Definitions from Article 2 of the
Nagoya Protocol:

UN

United Nations

•

“Utilization of genetic resources” means
to conduct research and development
on the genetic and/or biochemical composition of genetic resources, including
through the application of biotechnology
as defined in Article 2 of the Convention;

TBD

To Be Determined

EU

European Union

NGO

Non-Governmental Organization

GR

Genetic Resource

“Derivative” means a naturally occurring
biochemical compound resulting from
the genetic expression or metabolism
of biological or genetic resources, even
if it does not contain functional units of
heredity.

TK

Traditional Knowledge

MATs

Mutually Agreed Terms

IP

Intellectual Property

•

•

LMOs Living Modified Organisms
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Executive Summary
This report assesses how implementation of
the Nagoya Protocol on Access and Benefit
Sharing (NP) to the Convention on Biological
Diversity (CBD) may affect U.S. researchers
working in the area of synthetic biology. It
also analyzes selected provisions in CBDrelated national legislation predating the NP
that may be relevant for such researchers.
The report concludes that numerous questions remain unanswered, both with respect
to the time period covered by CBD/NP and
with respect to what sorts of genetic material
are covered. Despite this uncertainty, and
despite the fact that the U.S. is not a party

to the CBD/NP, U.S. researchers would be
well-advised to:
1. inquire into the origin of tangible genetic
material that they use and, where applicable, to
2. ensure that such material was taken in
compliance with the domestic law of a
provider country
With respect to digital genetic information,
determining origin is likely to be more difficult.
Even so, provider countries may assert that
such information falls within the scope of the
CBD/NP.

Synthetic Biology and Genetic Resources
Synthetic biology aims to take genetic engineering to a new level. Whether this new level
will ultimately be revolutionary or evolutionary
remains to be seen. Revolutionary advances
might allow full-scale application of engineering principles like standardization, decoupling
of information from manufacture, and abstraction, with the result that well-characterized DNA parts could readily be assembled in
many different ways to generate predictable
outputs.1 On the other hand, if current levels
of unpredictability in biology continue to
perplex researchers,2 synthetic biology may
be better understood as a suite of evolutionary advances in DNA synthesis and system
modeling that allow more rapid design of new
microbial systems.3
Regardless of how the technology develops
in the future, synthetic biology research into
improving DNA sequences (including not
only full sequences that code for proteins but
also sequences that have other functions)
has already utilized significant quantities
of tangible genetic material.4 Additionally,
the emergence of firms that can synthesize

relatively long DNA sequences accurately
has highlighted the central role of intangible
genetic information.5
For purposes of compliance with the CBD/
NP, one key question is whether particular
genetic material and information represents
“genetic resources.” As shown in the glossary,6 the CBD and NP define “genetic resources” to mean “genetic material of actual
or potential value.” Genetic material, in turn,
means any material that contains “functional
units of heredity.”
Neither the CBD nor the NP defines “functional units of heredity.”7 Thus it is unclear
whether all categories of DNA sequences
are covered. In addition, important questions regarding the reach of the CBD/NP into
intangible genetic information or so-called
derivative products remain unanswered. We
address these issues in the Implementation
Issues Section. Before addressing these and
other specific issues of implementation, however, we provide relevant historical and policy
background on the CBD/NP, particularly with
respect to the U.S. role.
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Background on the Convention on Biological
Diversity and the Nagoya Protocol
The CBD is designed to facilitate the conservation of biological diversity, the sustainable
use of its components, and the fair and equitable sharing of the benefits generated by
the use of genetic resources.8 It establishes
that genetic resources should be viewed not
as the common heritage of mankind, freely
available to all, but instead as the property
of sovereigns who make access to them
available under principles of prior informed
consent (PIC) and access and benefit sharing
(ABS).9
The CBD is an environmental treaty in the
sense that it was driven by a desire to stem
the uncontrolled depletion of flora and fauna
diversity, largely in the global south. But the
agreement was also designed to address
concerns relating to “biopiracy.” Biopiracy
has been defined as “[t]he patenting of
plants, genes, and other biological products that are indigenous to a foreign country
without compensating the keepers of those
resources and the holders of knowledge
appropriated during ethnobiological research
processes.”10 Compensation, in turn, would
presumably provide an incentive for appropriate biodiversity conservation going forward.
The CBD has 193 members and went into
effect in 1993. Its key principles include the
following:

•

States have sovereign control over
biological resources within their borders
and shall ensure conservation of same
(Art. 3);

•

States shall endeavor to create conditions to facilitate access on mutually agreed terms and subject to prior
informed consent (Art. 15(2));

•

There should be fair and equitable
sharing of benefits of use of genetic
resources with the providing party (Art.
15(7)); and

•

Any wider application of traditional
knowledge (TK) shall be with the approval and involvement of TK holders
(Art. 8(j)).11

Although then-President Bill Clinton signed
the CBD in 1993 on behalf of the United
States, the treaty was never ratified by the
U.S. Senate. Consequently, the United
States is not a party to either the CBD or
the NP. The U.S. is also opposed to CBDimplementing legislation in many countries
which, for example, links ABS/PIC obligations
with patent protection through a disclosure
of origin requirement for genetic resources
used in creating an invention. (See Box: U.S.
Opposition to linking ABS/PIC) For example,
as discussed later, the 2009 amendments to
the Chinese Patent Act included provisions
requiring patent applicants to disclose the
country of origin of relevant genetic resources
used in creating an invention and denying
patent protection to inventions created with
genetic resources obtained in violation of
Chinese law.
In addition, for many years, a number of
countries rich in genetic resources (so-called
“provider countries”) have been pressing in
several multilateral fora for ABS/PIC treaty
provisions and a new Disclosure of Origin
(DOO) patentability requirement. Such efforts
have generally been consistent with, and
designed to give effect to, the CBD. Many of
these countries also have created, or are in
the process of creating, biodiversity legislation, first to comply with the CBD and more

recently to implement the NP after it comes
into force. Most countries do not view treaty
obligations as self-implementing; rather, they
must be incorporated into domestic law by
implementing legislation.12
Most countries embrace dualism. However,
some dualist countries do allow treaties to
have direct effect in national law on a caseby-case basis.13 Implementing legislation
often is also necessary because treaty terms
may lack specificity regarding how obligations are to be met, leaving such details to
individual countries to decide.
The Conference of the Parties (COP) is the
governing body of the CBD and takes decisions at periodic meetings to advance implementation of the Convention. Its decisions
include the promulgation of the Cartagena
Protocol on Biosafety,14 which went into effect in 2003, adoption of the Bonn Guidelines
on Access to Genetic Resources and the
Fair and Equitable Sharing of the Benefits
Arising from their Utilization in 200215 (See
Appendix for full text of Bonn Guidelines)
and, at its Tenth meeting in 2010 Nagoya,
Japan, the Nagoya Protocol on Access and
Benefit Sharing to the Convention on Biological Diversity (“NP”). The Bonn Guidelines and
the NP were necessary because, while the
CBD obligated Parties to facilitate access
to their genetic resources, and to fairly and
equitably share benefits arising from the
utilization of genetic resources with provider
countries, it provided almost no detail on how
ABS should be accomplished in practice.16
Consequently, provider countries had wide
latitude in developing legislation to implement
the CBD, creating a miasma of legal uncertainty for users faced with often burdensome
rules for ABS/PIC that varied significantly
by country. Over the eighteen years that

elapsed between adoption of the CBD and
adoption of the NP, the Parties studied and
debated ways to move forward on this issue.
Although the Bonn Guidelines were a helpful
step in providing further specificity on ABS
and PIC, they are not binding on Parties.
The NP, as a binding agreement, is a logical
step in the evolution of a detailed framework
to reduce uncertainty and provide increased
uniformity for both users and providers of
genetic resources and associated TK.17
That said, whether the NP ultimately fulfills its
goal of bringing greater certainty and uniformity will depend on how it is implemented
and ultimately comes into effect. Although
the NP was adopted in 2010, it will not formally come into effect until ninety days after
the fiftieth instrument of ratification is deposited with the CBD. 18 Ninety-two countries
signed the agreement, and twenty-six have
ratified it at the time of this writing. Interestingly, some countries, such as China, that
are parties to the CBD, did not sign the NP
before the deadline for signatures passed.
Nevertheless, such countries can still accede to the Protocol at a later date, and even
countries not parties to the CBD can accede
to the Protocol as long as they also become
a contracting party to the CBD at the same
time. In addition to ratifying the NP, member
countries must enact legislation to implement the Agreement. It is expected that the
Agreement will come into effect in 2014 at
the earliest.
The NP has two main foci: access and user
compliance. The access provisions give
Parties significant leeway to decide whether
they wish to regulate ABS and require PIC for
their genetic resources. If a country decides
to regulate ABS/PIC, it then must implement
the rather detailed NP international access
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standards, which build on and incorporate
aspects of the Bonn Guidelines to create a
framework for ABS/PIC. Regarding usercompliance, the NP requires all Parties to
ensure that only legally acquired genetic
resources and associated TK are utilized in
their jurisdictions, to monitor user compliance
via checkpoints (e.g., when receiving public
funding), and allow for ABS contract disputes
to be resolved in court. However, the NP
allows a fair amount of Party discretion in
choosing particular user-compliance implementing measures.19

•

It specifies that, consistent with CBD
Art. 15, benefits arising from genetic
resource utilization shall be shared in a
fair and equitable way with the Providing
Party and shall be upon mutually agreed
terms (MAT) (Art. 5).

•

It encourages countries to explore the
need for and modalities of a global multilateral benefit sharing mechanism/fund
to facilitate benefit sharing (Art. 10).

•

It requires countries to designate national
focal points for access and benefit sharing, so as to make information available
to users, providers and the COP, on the
procedures for obtaining PIC and complying with ABS requirements (Art. 13).

•

It requires countries to designate one or
more checkpoints to collect information
from users of genetic resources when
users claim, for example, an intellectual property right relating to a product developed from genetic resource
utilization. It also provides for certain
government-issued permits to serve as
internationally recognized certificates
of compliance;20 evidence that covered
genetic resources have been accessed
in accordance with PIC/ABS on mutually
agreed terms (Art. 17).

•

Several of its Articles also deal with ABS
and PIC obligations when traditional
knowledge is used (e.g., Arts. 7 & 12).

The NP includes the following key provisions:

•

It is applicable to genetic resources covered by CBD Article 15, to the benefits
arising from the utilization of such resources, as well as to traditional knowledge associated with such resources
and benefits arising from utilization of
such knowledge (Art. 3).

•

It incorporates the definitions provided
in the CBD and additionally defines
“derivatives” and “utilization of genetic
resources” (Art. 2).

•

It leaves to the discretion of the parties whether to regulate access to
their genetic resources and associated
traditional knowledge, and require prior
informed consent and benefit sharing
(ABS/PIC). However, any parties choosing to require PIC must implement,
through binding legislation, the detailed
access standards specified in the Protocol (Art. 6).

Article 4 also explains how the NP relates
to other existing and future treaties, noting
that the NP does not affect Party rights and
obligations in relation to other existing agreements, except when exercising those provisions would seriously damage or threaten biological diversity. It also states that although
it is the instrument for implementing the ABS
provisions of the CBD, it does not apply
to Parties of other specialized international
agreements with ABS provisions that are
consistent with the objectives of the CBD and
NP in respect of the specific genetic resource
covered by the specialized instrument. Thus,
for example, the sharing of genetic resources
for food and agriculture is excluded from the
NP, as such are covered by the International
Treaty on Plant Genetic Resources for Food
and Agriculture (ITPGRFA).21
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U.S. opposition to linking ABS/PIC obligations with patent protection through a disclosure
of origin requirement for genetic resources used in creating an invention
A U.S. Group response to a 2010 AIPPI questionnaire on the “Requirement of Indicating the Source
and/or Country of Origin of Genetic Resources
and Traditional Knowledge in Patent Applications”
sums up the Position of the United States on this
issue:
While the United States has been monitoring the
proposals that have been made in a variety of fora
to allow or mandate that national patent legislation
require the declaration of the source of genetic
resources and traditional knowledge in patent
applications as well as demands for sharing of
benefits from the commercialization of products
utilizing them, the US government, with the strong
support of US companies, has taken the position
that these initiatives are unwise and unnecessary.*
A separate document explains reasons for the U.S.
position:
We further note that there appears to be a presumption by the proponents, without empirical
evidence, that an invention related to a genetic
resource is automatically based upon illegal access
or misappropriation absent concrete evidence to
the contrary. However. . . many genetic resources
are indeed commercially sold, legally obtained,
and independently researched and developed into
inventions. Even within publicly accessible inter-

national and national gene banks, there are many
resources where the country of origin is unknown.
Even assuming arguendo, that new disclosure
requirements could achieve the purported goals,
new patent disclosure requirements would be
unworkable given the absence of knowledge of
country of origin for numerous publicly available
resources. However. . . such new disclosure requirements create legal uncertainty and increased
burdens on the patent system, as well as negative
effects on benefit sharing, but will not prevent the
purported acts of misappropriation or bad patents.
These objectives must be accomplished through
national ABS systems upon access to the material
initially. These examples lead to the conclusion
that new patent disclosure requirements will not
achieve the desired objectives and that incorporation of such requirements in the patent system
would stifle innovation and undermine the patent
system.**
There are no pending bills or discussions that
would suggest that legislation will be introduced
on these issues within the United States. It should
also be noted that the United States is not a party
to the Convention on Biological Diversity [CBD],
and no pending legislation exists that would alter
that status.

*International Association for the Protection of Intellectual Property (AIPPI), Questionnaire February 2010: Special Committees Q 94—WTO/TRIPS and Q166—Intellectual Property and Genetic Resources, Traditional Knowledge and Folklore
on the Requirement of Indicating the Source and/or Country of Origin of Genetic Resources and Traditional Knowledge in
Patent Applications: Communication from the US Group (Apr. 7, 2010).
**Council for Trade-Related Aspects of Intellectual Property Rights, Communication by the United States, Article 27.3(b),
Relationship Between the TRIPS Agreement and the CBD, and the Protection of Traditional Knowledge and Folklore, IP/
C/W/469, para. 37 (Mar. 13, 2006). See also Jonathan Carr, Agreements That Divide: TRIPS vs. CBD and Proposals for
Mandatory Disclosure of Source and Origin of Genetic Resources in Patent Applications, 18 J. Transnat’l L. & Policy 131,
144 (2008) (discussing U.S. opposition to proposed TRIPS disclosure of origin amendments). Nevertheless, regulations
are apparently in place for U.S. government agencies to comply with CBD and Protocol requirements when engaging in
commercial and noncommercial scientific research. See Geoff Burton, Implementation of the Nagoya Protocol in JUSCANZ
Countries: The Unlikely Lot, p. 311, in The 2010 Nagoya Protocol on Access and Benefit-Sharing in Perspective: Implications
for International Law and Implementation Challenges, Elisa Morgera, Matthias Buck & Elsa Tsioumani, eds. (Martinus Nijhoff
Pub. 2012). While such provisions do not govern private sector and non-U.S.-government public sector research, certain
entities, such as the Biotechnology Industry Organization (BIO), have published best practice guidelines for members to
follow to comply with the CBD. See BIO, Guidelines for BIO Members Engaging in Bioprospecting, http://www.bio.org/
sites/default/files/Guidelines%20for%20BIO%20Members%20Engaging%20in%20Bioprospecting_0.pdf.

Implementation Issues
In this section, we address specific CBD/NP
implementation issues relevant for synthetic
biology researchers. These issues, which are
somewhat interrelated, include the impact
of legislation predating the NP, the temporal
scope of CBD/NP obligations, and the scope
of materials and information covered.
By way of preface, we note that the NP does
not explicitly address synthetic biology at
any point, nor does it appear that the topic
received much discussion during negotiations on the NP. A 2008 CBD ad hoc expert
group report did note that the term “derivative,” while not the subject of any common
understanding, denotes “a continuum of
very general to very specific concepts.” This
broad language is not, however, found in the
NP itself. The NP’s definition of a derivative is
discussed further below.
(c)

Gene segments produced or isolated
by human manipulation of genetic
material.

(d)

Synthetic gene segments produced by
human manipulation (one segment being a derivative of all the various genetic
materials used in its construction).

(e)

Information or knowledge derived from
genetic materials in general or a specific
gene sequence in particular.

(f)

Synthetic analogue chemicals or gene
segments inspired by a particular
naturally occurring metabolite or gene
segment. . . .

(j)

Something derived from biological and
genetic resources such as varieties,

strains or breeds, blood, proteins, oils,
resins, gums, genes, seeds, spores,
pollen, urine, bark, wood, leaf matter
and the like as well as the products
derived from, patterned on, or incorporating manipulated compounds and/or
genes[.]22
In Decision XI/11, adopted during the Eleventh COP meeting 9-18 October 2012 in
Hyderabad, India, the CBD COP requested
input from parties and other stakeholders on new and emerging issues relating to
the components, organisms and products
resulting from synthetic biology techniques
that may have impacts on the conservation and sustainable use of biological diversity and associated social, economic and
cultural considerations.23 This request is
further evidence of the lack of any meaningful discussion of, or consensus regarding,
the NP’s applicability to synthetic biology
inputs and products during negotiation of the
agreement. Draft documents submitted to
the COP in response to the request identify
a wide range of issues and uncertainties regarding the NP and synthetic biology that will
need to be resolved over time if there is to be
a harmonized approach to this topic.24 In the
meantime, individual countries seem free to
interpret their existing domestic biodiversity
legislation, or insert provisions in their draft
NP implementing legislation, to cover synthetic biology inputs and products. To date,
we have been unable to identify any country’s
legislation, draft or existing, that explicitly
addresses synthetic biology as such.25 That
said, as discussed below, language in certain
legislation may be deemed to encompass
activities conducted by synthetic biologists.
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Legislation Predating the NP
At least fifty-seven countries and seven
regions have some type of patchwork
biodiversity and/or ABS/PIC legislation for
implementing the CBD that predates the
NP.26 Such legislation, often contained in
biodiversity and/or patent laws, takes a wide
variety of forms.
China: For example, China has over fifty
biodiversity-related laws, at least some of
which regulate access and benefit sharing in
relation to genetic resources.27 The country
also incorporated genetic resource provisions
in the most recent (third) amendment to the
Chinese Patent Act which went into effect
in 2009.28 Article 5 of the Third Amendment
denies patentability to any invention created
using genetic resources obtained in violation
of Chinese law. 29 The new Article 5 states:
“Patents shall not be granted for
inventions or creations that violate
the law, run counter to social ethics
or jeopardize the public interest. If
genetic resources are obtained or
used in violation of laws or administrative regulations and an invention
or creation is completed on the basis
of such genetic resources, the patent shall not be granted therefor.”
However, once a patent has been granted, the
fact that it is later determined that the inventor
violated a Chinese genetic resource law would
not be a basis for invalidating that patent.
The implementing guidelines for the revised
Chinese Patent Act define genetic resources
to include genetic material extracted from

the human body, animals, plants, or microorganisms which contain functional units of
heredity. 30 In addition to Article 5, the revised
Act contains another provision related to genetic resource acquisition, Article 26, which
requires applicants to disclose the country of
origin of relevant genetic resources in addition to the direct supplier.31 Article 26, states
in part:
“For an invention or creation completed based on genetic resources,
the applicant shall give an account
in the patent application documents
of the direct origin and ultimate
origin of the genetic resources. If
the applicant is unable to give an
account of the ultimate origin, it/he/
she shall give the reason therefor.”
Failure to supply the required information is
a basis for rejecting claims in an application,
but apparently not for invalidating an already
issued patent.32
Brazil: The laws of some other countries go
further. For example, a Brazilian law regulating access to components of Brazilian
genetic heritage contains a variety of penalties for violation of genetic resource laws in
creating patentable inventions. Such penalties include: payment to the Federal Government of at least twenty percent of the gross
income or royalties from commercializing or
licensing the resulting product (benefit sharing); suspension or cancellation of the resulting patent, and much more. Additionally, the
origin of genetic material used in creating an
invention must be disclosed in the patent
application.33

India: India’s Biodiversity Act has even stiffer
penalties for applying for patent protection on
an invention created with genetic resources
obtained without complying with the ABS/
PIC provisions of the Act: fines and imprisonment, although the law does allow violators
to obtain the necessary permissions after the
fact. However, whether provider countries
actually enforce these laws consistently or
even arbitrarily, is unknown. (See Box, India’s
Biodiversity Act)34
Section 2 of the Act defines “biological
resources” as including plants, animals
and micro-organisms or parts thereof, their
genetic material and by-products. Unlike
the Chinese regime, India’s legislation does
not encompass human genetic material;
likewise, the NP, incorporating CBD Decision X/1, does not currently include human
genetic resources although that may be
further considered by the COP in the future.35
This wide diversity of approaches to ABS/
PIC was part of the impetus for negotiation
and adoption of the NP, especially as pre-NP
provider country legislation tends to focus on
illegal access and use of genetic resources
obtained from that country as opposed to
the NP’s more global focus on ensuring that
genetic resources and associated traditional
knowledge are acquired under the relevant
ABS/PIC legislation of any country from
which they are originally obtained. However,
as discussed below, the NP, while bringing uniformity to some aspects of ABS/PIC,
leaves several areas for continued member
country divergence.
Others: As of this writing, only six countries
and the EU have submitted, to the CBD COP,

implementing legislation for the NP and, in
most cases, that legislation is still in draft
form (and in a non-English language, namely
French, Danish, or Spanish). For example,
draft implementing legislation in Denmark
provides for fines and up to two years imprisonment for utilizing genetic resources acquired in violation of a given country’s access
regulations, so long as the activity in question
was willful or grossly negligent.36 Thus, entities that use genetic resources obtained from
a provider country in a manner that violates
the PIC/ABS legislation of the provider will
risk the imposition of penalties (civil and/or
criminal) against them not only in the provider
country but perhaps also in other countries
that penalize extraterritorial genetic resource
access violations. In addition, it is important
to remember that many provider countries
already have PIC/ABS legislation in effect
that complies with many of the requirements
of the NP despite predating it, and may thus
require only minimal adjustments (particularly
to harmonize with the NP’s access requirements) to be fully compliant.

Temporal Scope (Retroactivity)
As noted, the NP will come into effect ninety
days after fifty countries ratify the agreement.
But that fact does not resolve the question of
whether the agreement will apply to genetic
material acquired prior to the NP’s effective
date under conditions that would not satisfy its requirements. Indeed, an important
question not clearly addressed by the NP
and currently the subject of intense debate is
whether user obligations are triggered only at
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the time of initial resource access/removal or
extend to the time of utilization. This issue is
also referred to as temporal scope, with two
primary temporal triggers: CBD ratification
(1993) and NP ratification (TBD).37 Significant
genetic resources will have been accessed
in provider countries prior to the entry into
force of the NP (and others even before the
CBD). But new utilization of many of those
resources, currently held in gene or seed
banks, botanical gardens, or private collections outside the provider country, will take
place only after the effective date of the NP.
Legislation implementing the NP clearly will
make users of genetic material physically
accessed for the first time after the NP takes
effect subject to its obligations. However, it is
unclear if governments will impose NP obligations on entities making new uses of genetic
resources obtained from provider countries
prior to the entry into force of the NP.
Article 28 of the Vienna Convention on the
Law of Treaties, an agreement on treaty
interpretation, provides that a treaty does
not have retroactive effect unless the parties agree otherwise.38 Because the parties
to the NP were unable to agree on temporal
scope during the multiyear negotiations, the
Agreement is silent on the topic. This silence
does not, however, settle the question, as the
parties may also disagree on what represents
retroactivity. Provider countries may view a
utilization trigger as not prohibiting retroactivity but, rather, giving effect to the terms and
spirit of the NP.39 This is particularly likely
to be the case because more than twenty
such countries have, since 1993, enacted

PIC/ABS legislation with obligations tied to
access and/or utilization, to effectuate the
CBD. These countries include the Andean
Community (Bolivia, Columbia, Ecuador, and
Peru), Denmark, Ethiopia, India, Brazil, Kenya, Norway, Panama, the Philippines, South
Africa, and Vietnam.40
Definitions of what constitutes true access
are also contested. As two observers of the
NP negotiations explain:
One fairly common opinion among
user countries was that a genetic
resource is accessed at the point
in time when the biological sample
is crossing a border; by contrast,
provider countries often opined
that access occurs when biological
material is used for the purpose of
taking advantage of its genetic material, independent of when and under which conditions the biological
material actually crosses a border. .
. . To establish a functional system
for implementing the NP, countries
will need to agree on when “access”
happens.41
Because the NP is silent on “when access
happens,” user countries may choose to
implement the agreement in a manner that
imposes obligations only on genetic resources that cross a border after the NP comes
into force. That is the apparent approach of
the draft implementing legislation for the EU,
which states

Article 2: Scope
This Regulation applies to genetic
resources over which states exercise
sovereign rights and to traditional
knowledge associated with genetic
resources that are accessed after the
entry into force of the Nagoya Protocol
for the Union. It also applies to the
benefits arising from the use of such
genetic resources and to traditional
knowledge associated with genetic
resources. . . .42
The EU draft legislation is expected to
comprehensively implement only the usercompliance obligations of the NP by means
of a regulation, which will ensure the highest
level of harmonization because it will apply in
all member countries without implementing
legislation. However, the legislation leaves
member countries free to craft their own NP
implementing legislation to address ABS and
PIC if they so desire. Consequently, there is
expected to be no direct conflict between EU
and member state NP implementing legislation.43
Similarly, implementing legislation proposed
by Switzerland states that NP obligations
apply only to “access to genetic resources
or associated traditional knowledge that has
occurred after the said provisions came into
force.”44 Japan has also indicated that its
implementing legislation will not have what it
considers retroactive effect.45
The EU/Swiss approach has been criticized
by NGOs and a special European Commission rapporteur, all of which argue that to

achieve the goals of the NP and provide legal
certainty for users and providers, new uses
of genetic resources accessed prior to the
NP must be subject to its requirements.46
Under such a construction, genetic resources
acquired decades ago from a member country without complying with ABS/PIC, and
maintained in repositories in another country
during the intervening time period, would be
subject to the NP’s ABS/PIC requirements at
any future time they were used in research
and/or to create new products.
Similarly, the ABS Management Tool: Best
Practice Standard and Handbook for Implementing Genetic Resource Access and
Benefit Sharing Activities recommends that
users of genetic resources comply with the
domestic legislation in the providing country,
which would include legislation that makes
utilization the trigger for NP compliance.47
Parties pushing for a utilization trigger for Protocol obligations point to several concerns,
as explained in comments on the EU draft
legislation:
First, a significant share of GRs and
associated TK used in the EU will
not be covered by the Regulations,
thereby undermining the spirit of the
Nagoya Protocol. Second, individual
users of GRs and TK will not be
able to receive what they always
wanted: legal certainty. In many
cases, the utilization of GR and
TK will be legal under EU law, but
illegal under the law of the provider
country. Although the user has
received an approval from European
authorities, he or she could be pros-
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ecuted in a provider country upon
setting foot in that country. Nobody
is interested in such scenario.48
Consequently, the issue of the temporal
scope of the Nagoya Protocol obligations
remains very uncertain and is likely to stay
that way for the foreseeable future.

The Breadth of CBD/NP Coverage
In addition to temporal scope, issues regarding the scope of materials covered by the
CBD/NP remain unresolved. As noted in Part
II, an initial open question revolves around
what is meant by the term “functional unit
of heredity.” In the time period (1989-1992)
when the CBD was negotiated, the scientific
focus was on full gene sequences that coded
for proteins. Thus, at the time, the term may
have referred primarily to full sequences that
coded for proteins.49 By contrast, the DNA
“parts” that synthetic biology researchers
develop may represent only parts of coding regions or may emerge from non-coding
regions that regulate gene expression. It is
unclear whether a partial coding sequence or
a DNA sequence that regulates gene expression constitutes a functional unit of heredity.
In general, as biological science, including
synthetic biology, moves away from a focus
on individual full gene sequences towards
a focus on parts of genes as well as the full
genome and proteome, it is unclear how the
notion of a “functional unit of heredity” will map
onto the new science. Provider countries are
likely to argue that the term encompasses all
DNA sequences, while user countries may
argue for a narrower interpretation.

Provider countries may also point to a 2008
Report by a Working Group of Legal and
Technical Experts that specifically discusses
the utilization of genetic resources as encompassing “[g]enetic modification of a microorganism for a specific purpose” as well
as “use of genetic material as a ‘factory’ to
produce organic compounds.” As currently
practiced, synthetic biology does indeed use
genetically engineered micro-organisms (e.g.,
yeast) to produce chemical compounds such
as artemisinin, isoprene, and vanillin.50
With improvement in DNA synthesis technology, synthetic biology increasingly relies
on transfers of digital information rather than
transfer of physical material. The use of the
term “genetic material” in the CBD/NP suggests that intangibles do not fall within the
scope of the CBD/NP. On the other hand,
some have argued for a “broad and dynamic”
understanding of the concept of genetic
resources that would encompass digital information.51 In this regard, it is notable that the
Andean Community Commission’s Common
Regime on Access to Genetic Resources,
adopted in 1996, includes a reference to
genetic information. It defines genetic
resources as “all biological material that contains genetic information of value or of real
or potential use.”52 In addition, the Brazilian
Provisional Act of 2001 defines genetic heritage broadly as “information of genetic origin,
contained in samples of all or part of a plant,
fungal, microbial or animal species . . .” 53
Note that although sequence information
could conceivably be a genetic resource,
it is unlikely to have been derived from the
provider community and thus seems unlikely
to constitute traditional knowledge.

If the CBD/NP is deemed to cover sequence
information, and access is deemed to occur
when that information “crosses a border,”
(see discussion in Section IV.B), the issue
of what constitutes a border becomes an
interesting one. User countries, which have
pushed for a “crossing the border” definition
of access, might try to argue that the movement of digital information out of the country
should not be considered the equivalent of
crossing a physical border.
Further questions arise in the context of
so-called derivatives. As noted, synthetic
biology currently uses genetically modified
organisms to produce chemicals, such as
artemisinin, isoprene, and vanillin, which
have natural analogs.54 Article 2 of the NP
defines a derivative as “a naturally occurring
biochemical compound resulting from the
genetic expression or metabolism of biological or genetic resources, even if it does not
contain functional units of heredity.” Thus
various products of synthetic biology would
appear to fall within Article 2. However,
derivatives are not explicitly included in the
scope of Article 3, and thus commentators
differ on whether the NP’s obligations should
be deemed to extend to them or should be
confined to genetic resources.55
Like the controversy over temporal scope,
the controversy over the NP’s breadth,
particularly with respect to derivative products, is likely to pit provider countries against
user countries. Provider countries are likely
to view any use of genetic resources, even
uses much farther down the supply chain in
which the original genetic resource has been
very substantially modified, or comprises only

a very small part of the whole, as triggering
ABS obligations. Conversely, countries that
limit obligations to the time of accessing the
genetic resource may, to some degree, effectively limit the NP’s applicability to derivative products, as later uses of the resources
simply will not be known at the time the
genetic resource is accessed and the ABS
agreement is drawn up. Making the NP
applicable to derivative products could have
the negative effect of dis-incentivizing the use
of genetic resources in research and commercialization endeavors. By the same token,
denying the applicability of the NP to derivative products could result in provider countries
making access requirements more onerous
which could dis-incentivize research into previously un-accessed genetic resources.
One NP bright spot for researchers is the
Article 8 provision requiring Parties to create
“simplified measures on access for non-commercial research purposes.” This provision
was included in recognition of the need for
streamlined access to genetic resources for
initiatives such as the International Barcode
of Life (iBOL) project on DNA barcoding
species identification efforts.56 Article 8 does
suggest, however, that a change in the nature
of such research from non-commercial to
commercial would need to be addressed.

Relevance for Researchers
Article 15 of the NP requires each party to
take appropriate measures to ensure that genetic resources utilized within its jurisdiction
have been accessed in compliance with the
PIC/ABS domestic legislation of the providing country and that mutually agreed terms
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(MATs) have been established. Because the
United States is not a party to the NP, it is
not likely to impose any such requirement for
the use of genetic resources. Nevertheless,
U.S. researchers entering provider countries,
seeking to obtain new genetic resources from
such countries, or even seeking to obtain
intellectual property rights in any country
(including a user country) that has PIC/ABS
legislation over inventions developed with
genetic resources accessed and/or used in
violation of a provider country’s domestic legislation, may be subject to the range of legal
action specified in such legislation, including,
in some cases, imprisonment. Consequently, researchers in the United States would be
well-advised to:

•

Inquire as to the origin of genetic resources used in research and seek to

comply with the domestic legislation of
the identified provider country regarding PIC/ABS/ MAT (the ABS Handbook
provides a “best practices” approach).

•

Continue to monitor the development
of both NP implementing legislation in
member countries and the COP exploration of emerging issues under COP
Decisions VIII/10 and XI/11, including
synthetic biology and its relation to the
NP. Both in the submissions to the COP
and in the choice of agenda items for
future DOP meetings.57

•

Provide input and advice to legislators
in user and provider countries who are
drafting NP implementing legislation to
ensure concerns regarding synthetic
biology coverage, and temporal scope
are considered and addressed.

Box 2
India’s Biodiversity Act
The Biodiversity Act provides in part:
“6.
(1) No person shall apply for any intellectual property right by whatever name called in or outside
India for any invention based on any research or information on a biological resource obtained from India
without obtaining the previous approval of the National Biodiversity Authority before making such application:
Provided that if a person applies for a patent, permission of the National Biodiversity Authority may be
obtained after the acceptance of the patent but before the sealing of the patent by the patent authority
concerned.
(2) The National Biodiversity Authority may, while granting the approval under this section, impose
benefit sharing fee or royalty or both or impose conditions including the sharing of financial benefits arising
out of the commercial utilisation of such rights.
....
Penalties.
55.
(1) Whoever contravenes or attempts to contravene or abets the contravention of the provisions of
section 3, section 4, or section 6 shall be punishable with imprisonment for a term which may extend to
five years, or with fine which may extend to ten lakh rupees and where the damage caused exceeds ten
lakhs such fine may be commensurate with the damage caused, or with both . . .
57.
(1) Where an offence or contravention under this Act has been committed by a company, every
person who at the time the offence or contravention was committed was in charge of, and was responsible
to the company for the conduct of the business of the company, as well as the company, shall be deemed
to be guilty of the offence or contravention and shall be liable to be proceeded against and punished accordingly:
....
Provided that nothing contained in this sub-section shall render any such person liable to any punishment
provided in this Act, if he proves that the offence or contravention was committed without his knowledge or
that he had exercised all due diligence to prevent the commission of such offence or contravention.”

23

Synthetic Biology Project / The Nagoya Protocol and Synthetic Biology Research: A Look at the Potential Impacts
24

Conclusion
Significant genetic resources will have been
accessed in provider countries prior to the
entry into force of the NP (and others even
before the CBD). But new utilization of many
of those resources, currently held in gene or
seed banks, botanical gardens, or private
collections outside the provider country, will
take place only after the effective date of the
NP. Consequently, until countries agree on
the temporal scope of NP obligations (i.e.,
whether they apply only to materials accessed in a member country after ratification
of the NP or also to genetic materials accessed before, but utilized after, ratification
of the NP), there will continue to be a lack of
uniformity and legal uncertainty for researchers using genetic resources in their work.
Moreover, failure to comply with the ABS/PIC
provisions of any country may affect the ability of researchers to obtain IP rights, certain
kinds of funding, or other benefits in jurisdictions such as the EU.

Synthetic biology researchers, who often
work on DNA sequences that do not code for
a full protein, or with genetic information only,
face additional uncertainty. Neither the CBD
nor the NP defines “functional units of heredity.” Thus it is unclear whether all categories
of DNA sequences are covered. In addition,
important questions regarding the reach of
the CBD/NP into intangible genetic information or so-called derivative products remain
unanswered.
Implementation of the Nagoya Protocol by
member countries is in its infancy, thus many
questions regarding how the agreement will
be implemented cannot currently be answered. This can be seen as an opportunity
however, for researchers and other interested
parties to actively engage the political process in particular countries to provide input
into how the NP should be implemented.

Appendix
Bonn Guidelines
A major achievement of COP VI was the
adoption of the Bonn guidelines on access
to genetic resources and the fair and equitable sharing of the benefits arising from their
utilization (see Decision VI/24).
The Guidelines were recognized as a useful first step of an evolutionary process in
the implementation of relevant provisions of
the Convention related to access to genetic
resources and benefit-sharing. They will be
kept under review by the COP and the need
for their further refinement will be considered
on the basis of relevant developments under
the Convention, including those on issues
such as traditional knowledge and technology transfer.
The guidelines should assist Parties, Governments and other stakeholders in developing
an overall access and benefit-sharing strategy, and in identifying the steps involved in
the process of obtaining access to genetic
resources and benefit-sharing. More specifically, these voluntary guidelines are meant
to assist Parties, Governments and other
stakeholders when establishing legislative,
administrative or policy measures on access
and benefit-sharing and/or when negotiating contractual arrangements for access and
benefit-sharing.
Parties and relevant organizations have been
invited to provide financial and technical assistance to support developing countries, in
particular least developed countries, small
island developing states, as well as countries
with economies in transition, in implementing
the Bonn Guidelines.

The second meeting of the Ad Hoc Openended Working Group on Access and
Benefit-sharing, held in Montreal from 1 to
5 December 2003, considered experience
gained from the use of the Bonn Guidelines,
based on information shared by Parties and
stakeholders.
The Conference of the Parties at its seventh
meeting, in Decision VII/19 addressed the
Bonn Guidelines under section A. The COP
recognized “that the Guidelines are making
a useful contribution to the development of
national regimes and contractual arrangements for access and benefit-sharing and to
the implementation of the objectives of the
Convention”. It also recognized that some
developing countries had encountered constraints due to inadequate capacity to fully
utilize the guidelines in the formulation of their
national access and benefit-sharing legislation. Parties, Governments, indigenous and
local communities and all relevant stakeholders were invited to continue to promote the
wide implementation of the voluntary Bonn
Guidelines. They were also encouraged to
submit further information on relevant experience and lessons learned, including successes and constraints, in the implementation of
the Guidelines. The Executive Secretary is
to make this information available through
appropriate means, including the Clearing
House Mechanism of the Convention. Other
issues of relevance to the Bonn Guidelines
were also addressed by the Conference of
the Parties in Decision VII/19, such as the
use of terms, and other approaches, complementary to the Bonn Guidelines to assist with
the implementation of the ABS provisions of
the Convention.
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Appendix (continued)
At its eighth meeting, in decision VIII/4 B, the
Conference of the Parties noted the progress
already accomplished and urged Parties
to continue implementing the Bonn Guidelines and to share experiences and lessons
learned in their implementation as well as
in the development and implementation of
national and sub-national measures. Information provided to the Secretariat related to the
implementation of the Bonn Guidelines has
been compiled in information documents.58
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